Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2012-2018 - Analysis and Trends of Deal trends, Players, Financials & Forecasts

Dublin, March 06, 2018 -- The "Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2012-2018: Deal trends, players, financials and forecasts" report has been added to ResearchAndMarkets.com's offering.

The Global Cancer Monoclonal Antibody Partnering 2012-2018: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies. This report provides details of the latest Cancer monoclonal antibody agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all Cancer monoclonal antibody partnering deals announced since Jan 2012, including financial terms where available, including links to online deal records of actual Cancer monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

• Monoclonal antibodies
• Murine mAb
• Chimeric mAb
• Humanized mAb
• Human aAb

Key benefits

• In-depth understanding of cancer monoclonal antibody deal trends since 2012
• Access to headline, upfront, milestone and royalty data
• Access to the structure of cancer monoclonal antibody agreements with numerous real life case studies
• Comprehensive access to over 360 actual cancer monoclonal antibody deals entered into by the world's biopharma companies
• Identify most active companies in cancer monoclonal antibody partnering
• Insight into the terms included in a cancer monoclonal antibody agreement, together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies
• Spot the emerging companies in the cancer monoclonal antibody area

Report scope

Cancer Monoclonal Antibody Partnering Terms & Agreements includes:

• Trends in cancer monoclonal antibody dealmaking in the biopharma industry since 2012
• Analysis of cancer monoclonal antibody deal structure
• Access to headline, upfront, milestone and royalty data
• Access to over 360 cancer monoclonal antibody deal records
• The leading cancer monoclonal antibody deals by value since 2012

In Cancer Monoclonal Antibody Partnering Terms & Agreements, the available deals are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific oncology therapy target
• Monoclonal antibody type

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Cancer monoclonal antibody dealmaking

Chapter 3 - Leading Cancer monoclonal antibody deals

Chapter 4 - Most active Cancer monoclonal antibody dealmakers

Chapter 5 - Cancer monoclonal antibody contracts dealmaking directory

Chapter 6 - Cancer monoclonal antibody dealmaking by technology type

Chapter 7 - Partnering resource center

For more information about this report visit https://www.researchandmarkets.com/research/qbc7xn/global_cancer?w=12

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Biotechnology, Oncology Drugs , Biopharmaceuticals